Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | KCNN2 | Q9H2S1 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14828507 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL14828500 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL15180363 | 0.83 | HTR2A (0.47) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL15432201 | 0.83 | HTR2A (0.47) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL7436614 | 0.81 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL7911834 | 0.81 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL31936524 | 0.81 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL3801546 | 0.81 | NQO2 (0.44) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL383341 | 0.81 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B | |
| SCHEMBL31549 | 0.81 | CYP3A4 (0.43) | CYP3A4MAPTNQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| EP-2393784-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | Les Laboratoires Servier (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089475-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | CYP3A4 15/4885MAPT 4588/4885NQO2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.